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Long term effects and clinical outcome of low-dose azithromycin in 
young patients with cystic fibrosis: a multicenter, randomized, 
double-blind, placebo-controlled trial 
A. Clement 1, A. Tamalet 1,E. Le Roux 9, S. Ravil ly 2, J.P. Jais ~ 
~Pediatric Pulrnonology, Trousseau Hospital, Paris. 2Association Y~inere la 
Mucoviscidose, Paris. SBiostatistics, Necker Hospital, Paris 
Aims : Macr olides are known to display immtmo modulatory effects that have been 
reported to be beneficial in various cbr onic pulmonary ilfflammatory diseases. The 
aim of the study was to document whether long term use of azitbromycin may be 
associated with respiratory benefits in young patients with cystic fibrosis (CF). 
Metku~ds : The study was a multi~center (18 CF centers in France), randomised, 
double bl ind placebo controlled trial, conducted from October 2CO1 to June 2CO3. 
The criteria for enrolment were a diaguosis of CF, age older than 6 yr, and forced 
expiratory volume ha 1 second (FEV1) of 40% or more. The azitbromycin (Az) 
group received either 250 mg (weight <4Okg) or 500 mg (weight >40kg) for 1 year. 
Results : 72 patients (mean age : 10.9 + 3.4 yr) were randomly assigned treatment 
and analysed. Only 15 patients were infected with Pseudomonas aeruginosa. The % 
predicted FEV1 at start of trial in the Az and placebo (Pl) groups was respectively 
88.7 + 25.7% mad 85.6 + 18.1%. The relative change in FEV1 at the end of the trial 
was not significantly different between the 2 groups (Az: 5+18% vs Pl: 1+14%). By 
contrast, the average number of pulmonary exacerbations was significantly reduced 
ha the Az  group (p<0.CO2) regardless the infectious tatus, as wel l  as the number of 
additional antibiotic courses (p<0.CO2). No adverse vents were repotted. 
Conclusions : Results obtained in this first report of long term trial with low doses 
azitbromycine in young patients with CF demonstrate a benefit on lung disease 
expression, even prior colonization with Pseudomonas aeruginosa. 
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Evaluation of the observance of inhaled Tobramycin (TON®), by 
comparing the duration of dispensary delivery with the medical 
prescription in cystic fibrosis 
M. Thui l l ier l, N. Donnadieu l, C. Legui l lon 2, L. Couderc 2, S. Dominique 2, C. 
Marguet 9 
~Pharmacy department, 2Cystic Fibrosis reference center (CRCM) CHU Charles 
Nicolle Rouen, France 
Time spent for nebulizations made compliance as a major task in CF management. 
On the other hand, long term b.i.d nebulization of Tobi® was recommended in 
pseudomonas aeruginosa (PA) cbronic colonization. To evaluate the relevance of 
long term prescription regarding a realistic prescription, we assess compliance by 
comparing the dispensary Tobi® delivery with the medical prescription. 
Method: In France, Tobi® was delivered to the patient only from hospital Pharmacy. 
Then, Tobi® dispensary delivery (DD) was prospectively mad exhaustively 
registered by using a drug management retrocession software (Gest'cess®, 
Symphony online ltd) and compared with the corresponding medical prescriptions 
(MP). DD represented the effective and MP the recommended administration f the 
drug and were expressed in month of treatment. A ratio DD/MP 1 defined 
compliant (C) and DD/MP<I non compliant patients (NC). Treatment arrest for 
adverse ffect were excluded. 
Result: From 1999 to 2CO3, 42 patients (23 children,19 adults) were included 
(median age 14.5 years) and 26 were C and 16 NC. Median MP duration was longer 
than that in DD 8[6 16] vs. 6 [6 12] mths (p<0.CO1). A strong inverse correlation 
was found between DD/MP ratio and the recommended duration of Tobi® (Rho 
0.697, p<0.CO1). DD/MP was dependent on the indication (p~).002) but not age. 
Mult ivar iate analysis showed that compliance was only dependent on MP 
(p<0.001). A treatment > 6 months decreased ramatically the compliance (OR 19 
[ 3.4 105.7]. 
Conclusion: Our results s~aggest that a realistic prescription should not exceed a 6 
months Tobi® course. This study confirmed the high frequency of non observance 
in inhaled t obr amycin treatment, by using an objective method. We demonstrate hat 
chemist by using a drug management software provided a useful compliance index 
to the practitioner. 
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Long-term azithromycin (AZM) in Cystic Fibrosis (CF) children 
infected with Pseudomonas aeruginosa (Pa) 
I. Scatt olin 1, A. Hoffmann 1, F.A.A. Silva 1"~ 
iPediatric Pneurrmlogy Unit, Hospital de Clinicas de Porto Alegre, RS, Brazil, 
2Federal University of  Rio Grande do Sul, Brazil 
The aim of this study is to describe retrospectively the long term effect of AZM on 
pulmonary function a d sputum microbiology in CF patients infected with Pa. 
Mettu)cls: The case files of CF children who took AZM for at least one year were 
reviewed. 33 patients infected with Pa received AZM on a regular basis, 3 t imes a 
week. Al l  patients attended the outpatient clinic every 2 months mad sputum samples 
or tbroat s~v abs for microbiological nalysis were obtained. During AZM treatment 
cbronic infection was defined by the presence of 3 positive cultures ha one year. 
Patients > 6 y performed lung function tests once a year. Student t est was applied 
for statistical nalysis of %FEV1; p value < 0.05 considered significant. Results 
were presented as median (range) values. 
Results: 33 patients were included. Median age at start of treatment was 6.7 y 
(1.2 14.8). The duration of treatment varied from 17 to 53 months. 15 patients 
performed lung function tests. Median % FEV1 before treatment was 78 (58 121). 
4 different treatment periods were analysed: 5 15mo, 16 21mo, 28 34mo and 
35 49mo. The %FEVlchanges were, respectively, 75.5(61 102), 85(69 96), 
86,5(48 107), 95.5(38 107). No significant differences were observed. 23 patients 
(69%) showed no alteration ha the microbiologic profile during AZM. New 
pathogens were identified in 6 patients (18%): S aureus (3 patients); MRSA 
(1patient), Alc. xylosidans (1patient) and M. tuberculosis (1patient). ha 4 patients 
(12.1%) the fol lowing previously identified pathogens were no longer present: Pa 
and S aureus (2 patients), Pa (2 patients). 
Conclusions: Historical controls s~aggest that a decl ine in FEV1 would be more 
l ikely expected i f  conventional treatment had been given. The fact that no 
significant changes in FEV1 were seen during this long term treatment suggests that 
AZM may be responsible for the maintenance of lung function in CF patients. No 
specific pattern could be identified in the microbiological profiles during AZM 
treatment. A controlled prospective trial is needed to confirm these findings. 
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Lung function, serum immunoglobulin G subclasses and 
serum/sputum IL-8 levels in CF patients 
I. Stehnach, A. Kor zeniewska, P. Majak  
Department of  Pediatrics a~ul Allergy, M Curie Hospital, Zgiet~ Pola~ul 
Aim: This study was undertaken to define a correlation between lung function, 
serum immtmoglobuline G (IgG) subclasses and serum/sputum IL  8 levels in 
patients with CF. 
MatetiaI and methods: We examined 17 clinical stable CF patients aged 12 30. Al l  
patients were cbronic infected with Pseudomonas aeruginosa. FEV1 and VC were 
measured. Total IgG, IgG1, IgG2, IgG3, IgG4 (mg/dl) in serum mad serum/sputum 
IL  8 levels (pg/dl) were determined. 
Results: Mean FEV1 and VC were 57,2+23,5% and 66,4+25,9% predicted 
respectively. Mean total IgG levels were 1510+556,9, IgG1 9,552+2,51, IgG2 
4,8+2,04, IgG3 1,058+0,6 and IgG4 1,787+0,725. Mean serum mad sputum IL 8 
levels were 19,9+3,4 and 557,1+374,5. 
We found significant cotTelation between elevated total serum IgG levels and 
decreased FEV1 (p~),006). H igh levels of IgG2 were significantly correlated with 
decreased FEV1 (p 0,021) and VC (p~),042) and significant correlation between 
IgG2 and sputum IL 8 (p<K)8) levels was observed. There was significant 
correlation between elevated l vels of IgG4 and increased FEV 1 (p~),013) and VC 
(p~),023). Significant inverse cotTelation between IgG4 levels mad serum (p~),CO3) 
and sputum (p 0,CO2) IL  8 levels were observed. We found significant inverse 
correlation between FEV1 and sputum IL 8 levels (p~),024) and between VC mad 
serum/sputum IL  8 levels (p<0,001). 
Conclusions: Elevated IgG2 levels could be a useful marker of inflammatory 
prccess in CF patients cbronic infected with Pseudomonas aeruginosa nd high 
levels of IgG2 could be a sign of poor prognosis in this population. Elevated levels 
of IgG4 may ant agonise IgG2 helping to preserve relatively good pulmonary status. 
